Binghai Zhou

771 total citations
24 papers, 499 citations indexed

About

Binghai Zhou is a scholar working on Molecular Biology, Oncology and Hepatology. According to data from OpenAlex, Binghai Zhou has authored 24 papers receiving a total of 499 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Hepatology. Recurrent topics in Binghai Zhou's work include Cancer Immunotherapy and Biomarkers (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers) and Cancer, Lipids, and Metabolism (3 papers). Binghai Zhou is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers) and Cancer, Lipids, and Metabolism (3 papers). Binghai Zhou collaborates with scholars based in China, Ethiopia and Taiwan. Binghai Zhou's co-authors include Qing‐Hai Ye, Lei Guo, Jiuliang Yan, Mincheng Yu, Jia Fan, Yong‐Sheng Xiao, Yongfeng Xu, Bin Jin, Zheng Chen and Gang Du and has published in prestigious journals such as SHILAP Revista de lepidopterología, Biochemical and Biophysical Research Communications and Frontiers in Immunology.

In The Last Decade

Binghai Zhou

24 papers receiving 495 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Binghai Zhou China 13 207 175 129 126 97 24 499
Nina Waldburger Germany 13 201 1.0× 119 0.7× 149 1.2× 63 0.5× 100 1.0× 19 456
Tae Sung Ahn South Korea 15 255 1.2× 105 0.6× 294 2.3× 100 0.8× 66 0.7× 45 602
Guocheng Jiang China 9 272 1.3× 147 0.8× 265 2.1× 85 0.7× 30 0.3× 11 593
Sheng Han China 17 355 1.7× 200 1.1× 100 0.8× 89 0.7× 43 0.4× 33 586
Yu Yin China 13 329 1.6× 254 1.5× 106 0.8× 35 0.3× 40 0.4× 30 525
Yingqiu Y. Liu United States 7 461 2.2× 260 1.5× 175 1.4× 72 0.6× 63 0.6× 8 649
Yuichi Sanada Japan 14 235 1.1× 115 0.7× 244 1.9× 65 0.5× 37 0.4× 30 576
Qingmin Fan China 9 279 1.3× 155 0.9× 315 2.4× 277 2.2× 124 1.3× 15 685
Hongbing Shi China 12 159 0.8× 89 0.5× 321 2.5× 204 1.6× 66 0.7× 25 626
Yifei Mu China 14 228 1.1× 133 0.8× 140 1.1× 94 0.7× 35 0.4× 27 457

Countries citing papers authored by Binghai Zhou

Since Specialization
Citations

This map shows the geographic impact of Binghai Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Binghai Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Binghai Zhou more than expected).

Fields of papers citing papers by Binghai Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Binghai Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Binghai Zhou. The network helps show where Binghai Zhou may publish in the future.

Co-authorship network of co-authors of Binghai Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Binghai Zhou. A scholar is included among the top collaborators of Binghai Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Binghai Zhou. Binghai Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Zheng, Mincheng Yu, Bo Zhang, et al.. (2024). SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion. OncoImmunology. 13(1). 2376264–2376264. 3 indexed citations
2.
Chen, Sisi, Binghai Zhou, Wei Huang, et al.. (2023). The deubiquitinating enzyme USP44 suppresses hepatocellular carcinoma progression by inhibiting Hedgehog signaling and PDL1 expression. Cell Death and Disease. 14(12). 830–830. 9 indexed citations
3.
Xiong, Ming, Jie Liu, Peiyi Xie, et al.. (2023). Exosomes with IR780 and Lenvatinib loaded on GPC3 single-chain scFv antibodies for targeted hyperthermia and chemotherapy in hepatocellular carcinoma therapy.. PubMed. 13(11). 5368–5381. 5 indexed citations
4.
Xie, Peiyi, Jiuliang Yan, Hui Li, et al.. (2022). CD44 potentiates hepatocellular carcinoma migration and extrahepatic metastases via the AKT/ERK signaling CXCR4 axis. Annals of Translational Medicine. 10(12). 689–689. 13 indexed citations
5.
Chen, Zheng, Shuang Liu, Peiyi Xie, et al.. (2022). Tumor-derived PD1 and PD-L1 could promote hepatocellular carcinoma growth through autophagy induction in vitro. Biochemical and Biophysical Research Communications. 605. 82–89. 21 indexed citations
6.
7.
Zhang, Bo, Shuang Liu, Binghai Zhou, et al.. (2021). High serum gamma-glutamyl transpeptidase concentration associates with poor postoperative prognosis of patients with hepatitis B virus-associated intrahepatic cholangiocarcinoma. Annals of Translational Medicine. 9(1). 17–17. 2 indexed citations
8.
Yan, Jiuliang, Binghai Zhou, Lei Guo, et al.. (2020). GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma.. PubMed. 10(11). 3705–3720. 16 indexed citations
9.
Yu, Mincheng, et al.. (2020). QSOX1 promotes mitochondrial apoptosis of hepatocellular carcinoma cells during anchorage-independent growth by inhibiting lipid synthesis. Biochemical and Biophysical Research Communications. 532(2). 258–264. 7 indexed citations
10.
Zhang, Bo, Binghai Zhou, Min Xiao, et al.. (2020). KDM5C Represses FASN-Mediated Lipid Metabolism to Exert Tumor Suppressor Activity in Intrahepatic Cholangiocarcinoma. Frontiers in Oncology. 10. 1025–1025. 28 indexed citations
11.
Zhou, Binghai, Jiuliang Yan, Lei Guo, et al.. (2020). Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma. Theranostics. 10(14). 6530–6543. 48 indexed citations
12.
Chen, Zheng, Mincheng Yu, Lei Guo, et al.. (2020). Tumor Derived SIGLEC Family Genes May Play Roles in Tumor Genesis, Progression, and Immune Microenvironment Regulation. Frontiers in Oncology. 10. 586820–586820. 14 indexed citations
13.
Yan, Jiuliang, Binghai Zhou, Hui Li, Lei Guo, & Qing‐Hai Ye. (2020). Recent advances of GOLM1 in hepatocellular carcinoma. SHILAP Revista de lepidopterología. 7(2). HEP22–HEP22. 15 indexed citations
14.
Gao, Zhendong, Gang Du, Zhihao Fu, et al.. (2017). Adjuvant transarterial chemoembolization after radical resection contributed to the outcomes of hepatocellular carcinoma patients with high-risk factors. Medicine. 96(33). e7426–e7426. 23 indexed citations
15.
16.
Jin, Bin, Binghai Zhou, & Sanyuan Hu. (2015). Liver Exposure Using Sterile Glove Pouch During Laparoscopic Right Liver Surgery in Hepatocellular Carcinoma Patients. World Journal of Surgery. 40(4). 946–950. 5 indexed citations
17.
Tang, Zhenyu, Binghai Zhou, Wei Wang, et al.. (2015). Curative Analysis of Several Therapeutic Methods for Primary Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.. PubMed. 62(139). 703–9. 3 indexed citations
18.
Zhou, Hong, et al.. (2010). Toll-like receptor (TLR)-4 mediates anti-β2GPI/β2GPI-induced tissue factor expression in THP-1 cells. Clinical & Experimental Immunology. 163(2). 189–198. 33 indexed citations
19.
Zhou, Binghai, et al.. (2001). [Study on some metal elements levels and the T lymphocyte subset of the peripheral lymphocytes in patients with nasopharyngeal carcinomas].. PubMed. 15(11). 503–4. 1 indexed citations
20.
Zhou, Binghai, et al.. (2000). [Determination of the immune function of the erythrocyte and leucocyte and the activity of IL-4 and IFN-gamma in patients with allergic rhinitis].. PubMed. 35(6). 451–3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nina Waldburger Breakdown of academic impact, for papers by Tae Sung Ahn Breakdown of academic impact, for papers by Guocheng Jiang Breakdown of academic impact, for papers by Sheng Han Breakdown of academic impact, for papers by Yu Yin Breakdown of academic impact, for papers by Yingqiu Y. Liu Breakdown of academic impact, for papers by Yuichi Sanada Breakdown of academic impact, for papers by Qingmin Fan Breakdown of academic impact, for papers by Hongbing Shi Breakdown of academic impact, for papers by Yifei Mu
Rankless by CCL
2026